Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

Dong-shan Zhu; Jing-yao Dong; Yao-yao Xu; Xin-tong Zhang; Shi-bo Fu; Wei Liu

doi:10.12659/MSM.927106

17 August 2020 : Animal Research

Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

Dong-shan Zhu^1ABCDEF, Jing-yao Dong^1BCF, Yao-yao Xu^2BCD, Xin-tong Zhang^2BCD, Shi-bo Fu^2ACEFG, Wei Liu^1ACEFG*

DOI: 10.12659/MSM.927106

Med Sci Monit 2020; 26:e927106

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 PIK3CA and mTOR were highly expressed in Esophageal squamous cell carcinoma (ESCC) patients. (A, B) The PIK3CA and mTOR expression levels in all tumor samples. (C, D) The PIK3CA and mTOR mRNA expression in esophageal cancer samples and normal tissues (* P<0.05).

Back to the Article

Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

Your Privacy